Haemonetics Corp (NYSE: HAE) grants director Diane Bryant 2,538 restricted stock units

Rhea-AI Filing Summary

Bryant Diane M reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Diane M. Bryant received a grant of 2,538 restricted stock units on July 24, 2026 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and each unit represents a contingent right to receive one share of common stock when vested. Following this award, Bryant holds 9,664 shares of Haemonetics common stock directly.

Insider Trade Summary

Net Buyer: 2,538 shares

Net Buy 1 txn

Insider Bryant Diane M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	2,538	--	--

Holdings After Transaction: Common Stock — 9,664 shares (Direct)

Footnotes (2)

1. F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
2. F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSUs granted: 2,538 units Shares owned after transaction: 9,664 shares Vesting schedule: 100% after one year

3 metrics

RSUs granted 2,538 units Restricted stock units awarded to Diane M. Bryant on July 24, 2026

Shares owned after transaction 9,664 shares Direct beneficial ownership by Diane M. Bryant following the award

Vesting schedule 100% after one year RSUs vest 100% on the first anniversary of the grant date

Key Terms

restricted stock units, contingent right, Amended and Restated 2019 Long-Term Incentive Compensation Plan

3 terms

restricted stock units financial

"The securities awarded are in the form of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one (1) share"

Amended and Restated 2019 Long-Term Incentive Compensation Plan financial

"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:52 PM Accepted by SEC EDGAR 07/28/2026 - 04:52 PM Learn about SEC filing dates

FAQ

What did Haemonetics (HAE) director Diane M. Bryant receive in this Form 4 filing?

Diane M. Bryant received a grant of 2,538 restricted stock units (RSUs) on July 24, 2026. The award was made under Haemonetics Corporation’s Amended and Restated 2019 Long-Term Incentive Compensation Plan as part of her director compensation.

What is the vesting schedule for Diane M. Bryant’s new RSUs at Haemonetics (HAE)?

The 2,538 RSUs vest 100% on the first anniversary of the July 24, 2026 grant date. Once vested, each RSU will convert into one share of Haemonetics common stock, increasing her directly owned shares at that time.

How many Haemonetics (HAE) shares does Diane M. Bryant own after this RSU grant?

After the reported award, Diane M. Bryant beneficially owns 9,664 shares of Haemonetics common stock directly. This figure reflects her holdings following the grant of 2,538 restricted stock units reported in the Form 4.

Are the securities in this Haemonetics (HAE) Form 4 a market purchase or an award?

The transaction is an award of restricted stock units, not an open-market purchase. It is coded as a grant or award acquisition under the company’s 2019 Long-Term Incentive Compensation Plan rather than a buy or sell on the market.

What does each RSU granted to Diane M. Bryant by Haemonetics (HAE) represent?

Each RSU represents a contingent right to receive one share of Haemonetics common stock upon vesting. No share is issued until vesting occurs, at which point common stock is delivered on a one-for-one basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bryant Diane M

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		A		2,538(1)	A	(2)	9,664	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Ms. Bryant	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)